DEALS ANALYSIS
Deals activity: global decline in growth for drinks
Powered by
Deals activity by geography
Drinks industry deals, as captured by GlobalData’s Consumer Intelligence Centre, are down year-on-year (YoY) across all regions.
North America is leading in terms of deal value, but also recorded a decrease in YoY growth in deals volume at -38.42%. South and Central America, ranking last in terms of deal value, also suffered a downward YoY change, with deal volumes at -14.29%.
The volume of deals recorded by GlobalData also decreased YoY in Asia-Pacific (-20.83%), Europe (-31.25%), and Middle East and Africa (-36.36%).
Deals activity by type
| Deal type | Total deal value (US$m) | Total deal count | YoY change (volume) |
| Acquisition | 12,153 | 72 | 35.29 |
| Asset Transaction | 4,478 | 19 | -784.99 |
| Equity Offering | 1,646 | 19 | -32.08 |
| Venture Financing | 1,183 | 83 | 144.29 |
| Debt Offering | 12,708 | 21 | -78.59 |
| Partnership | 0 | 3 | N/A |
| Private Equity | 4,505 | 12 | 2623.24 |
| Merger | 4500 | 2 | N/A |
A breakdown of deals by type and volume shows a mixed trend, with negative YoY change showing in asset transaction (-784.99%), debt offerings (-78.59%), and equity offerings (-32.08%). Acquisitions are up 35.29%, venture financing up 144.29%, and private equity deals increased by 2623.24% YoY.
Deals activity by sector
Ecomerce deals lead the year so far, with 17 deals in total, and deals related to digitalisation follow in second place with four confirmed deals. Artificial intelligence, blockchain and cloud deals are at the end of the pack with one deal each.
Note: All numbers as of May 2021. Deals captured by GlobalData cover M&As, strategic alliances, various types of financing and contract service agreements.
For more insight and data, visit GlobalData's Consumer Intelligence Centre.
Latest deals in brief
Nestle to acquire Bountiful (Nature's Bounty) from KKR for $5.75bn
Nestle SA, a Switzerland-based food and beverage company, agreed to acquire Bountiful Co, a US-based manufacturer of nutritional supplements from KKR & Co. Inc. The transaction is valued at $5.75bn on a cash free, debt free basis, representing a multiple of 3.1x net sales and 16.8x EBITDA as of 31 March 2021.
One Rock Capital Partners and Metropoulos acquire Nestle Waters North America from Nestle
One Rock Capital Partners, LLC (One Rock), in partnership with Metropoulos & Co., has announced completion of the $4.3bn acquisition of Nestle Waters North America, a provider of bottled water in North America, from Nestlé S.A.
Kweichow Moutai raises $2bn in public offering of 3% Bonds
Kweichow Moutai Co., Ltd, a China-based producer of alcoholic beverages, has raised CNY13bn ($2bn) in public offering of bonds. The bond carry an interest rate of 3%. DeHeng acted as legal advisor for the transaction.
Keurig Dr Pepper raises $1,150m in offering of 0.75% senior notes due 2024
Keurig Dr Pepper Inc, a US-based coffee and beverage company, has raised $1,150m in offering of senior notes. The notes bear an interest rate of 0.75%, payable biannually on 15 March and 15 September, commencing on 15 September 2021, and will mature on 15 March 2024.
Danone Plans to Sell China Mengniu Dairy
Danone SA, a French food and beverage company, has announced its plan to sell its stake in China Mengniu Dairy Company Limited, a China-based manufacturer and distributor of dairy products and ice cream.
Danone’s indirect stake in Mengniu’s share capital currently represents a book value of approximately €850m ($1bn) and had in 2019 a contribution to recurring income from associates of €7m ($68.7m).
Rhizen signs oncology drug development deal with Curon
Swiss biopharma company Rhizen Pharmaceuticals has signed an exclusive licensing agreement with Curon Biopharmaceutical to develop and commercialise Tenalisib for oncology in the Greater China region. Tenalisib, a highly selective dual PI3K delta and gamma inhibitor, is currently in Phase II clinical development for haematological malignancies. The US FDA granted fast track and orphan drug designations for the drug candidate Tenalisib as a treatment for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
